As per the letter enclosed.
DRAGARWQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Dr Agarwals Eye Hospital approved the unaudited financial results for Q1 FY26 (quarter ended June 30, 2025) on August 12, 2025. Revenue from Operations rose to ₹116.92 Cr from ₹100.02 Cr in the same quarter last year, a growth of about 17%. EBITDA grew to ₹37.93 Cr (₹31.81 Cr YoY), while Profit Before Tax stood at ₹23.19 Cr versus ₹18.91 Cr. Net Profit After Tax increased to ₹17.26 Cr from ₹14.11 Cr, a YoY rise of roughly 22%. Diluted EPS came in at ₹36.72 versus ₹30.02 a year ago. The statutory auditors Deloitte Haskins & Sells issued a clean (unqualified) limited review report with no qualifications or emphasis-of-matter paragraphs. The company continues to operate in a single segment - Eye Care related sales and services.
A steady quarter with high single-digit revenue growth, expanding margins, and strong profit growth signals healthy business momentum for shareholders. The clean auditor review and double-digit PAT growth are positive indicators, though revenue growth fell just short of the 20% mark seen in earlier quarters.